Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome

被引:9
作者
He, Wenxiu [1 ]
Wei, Jiahe [1 ]
Liu, Xing [1 ]
Zhang, Zhongyin [1 ]
Huang, Rongjie [1 ]
Jiang, Zhiyuan [1 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiol, 6 Shuangyong Rd, Nanning 530021, Peoples R China
关键词
Glucagon-like peptide-1 receptor agonist; Semaglutide; Pressure overload; Cardiac hypertrophy; Mitophagy; NLRP3; inflammasome; LEFT-VENTRICULAR MASS; HEART-FAILURE; LIRAGLUTIDE; INJURY; MODEL;
D O I
10.1038/s41598-024-62465-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pathological cardiac hypertrophy is an important cause of heart failure(HF). Recent studies reveal that glucagon-like peptide-1 receptor (GLP1R) agonists can improve mortality and left ventricular ejection fraction in the patients with type 2 diabetes and HF. The present study aims to investigate whether semaglutide, a long-acting GLP1R agonist, can ameliorate cardiac hypertrophy induced by pressure overload, and explore the potential mechanism. The rats were performed transverse aortic constriction (TAC) to mimic pressure overload model. The rats were divided into four groups including Sham, TAC, TAC + semaglutide, and TAC + semaglutide + HCQ (hydroxychloroquine, an inhibitor of mitophagy). The rats in each experimental group received their respective interventions for 4 weeks. The parameters of left ventricular hypertrophy(LVH) were measured by echocardiography, Hematoxylin-eosin (HE) staining, western-blot and immunohistochemistry (IHC), respectively. The changes of mitophagy were reflected by detecting cytochrome c oxidase subunit II (COXII), LC3II/LC3I, mitochondria, and autophagosomes. Meanwhile, NLRP3, Caspase-1, and interleukin-18 were detected to evaluate the activation of NLRP3 inflammasome in each group. The results suggest that LVH, impaired mitophagy, and activation of NLRP3 inflammasome were present in TAC rats. Semaglutide significantly reduced LVH, improve mitophagy, and down-regulated NLRP3 inflammatory signal pathway in TAC rats. However, the reversed effect of semaglutide on cardiac hypertrophy was abolished by HCQ, which restored the activation of NLRP3 inflammasome suppressed by improved mitophagy. In conclusion, semaglutide ameliorates the cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP3 inflammasome. Semaglutide may be a novel potential option for intervention of cardiac hypertrophy induced by pressure overload.
引用
收藏
页数:11
相关论文
共 40 条
[1]   Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure [J].
Arturi, F. ;
Succurro, E. ;
Miceli, S. ;
Cloro, C. ;
Ruffo, M. ;
Maio, R. ;
Perticone, M. ;
Sesti, G. ;
Perticone, F. .
ENDOCRINE, 2017, 57 (03) :464-473
[2]   The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events [J].
Bluemke, David A. ;
Kronmal, Richard A. ;
Lima, Joao A. C. ;
Liu, Kiang ;
Olson, Jean ;
Burke, Gregory L. ;
Folsom, Aaron R. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (25) :2148-2155
[3]   BLOCKADE OF THE RENIN-ANGIOTENSIN SYSTEM IN CARDIAC PRESSURE-OVERLOAD HYPERTROPHY IN RATS [J].
BRUCKSCHLEGEL, G ;
HOLMER, SR ;
JANDELEIT, K ;
GRIMM, D ;
MUDERS, F ;
KROMER, EP ;
RIEGGER, GAJ ;
SCHUNKERT, H .
HYPERTENSION, 1995, 25 (02) :250-259
[4]   The Cardiovascular Biology of Glucagon-like Peptide-1 [J].
Drucker, Daniel J. .
CELL METABOLISM, 2016, 24 (01) :15-30
[5]  
Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986
[6]   Female sex and estrogen receptor-β attenuate cardiac remodeling and apoptosis in pressure overload [J].
Fliegner, Daniela ;
Schubert, Carola ;
Penkalla, Adam ;
Witt, Henning ;
Kararigas, George ;
Dworatzek, Elke ;
Staub, Eike ;
Martus, Peter ;
Noppinger, Patricia Ruiz ;
Kintscher, Ulrich ;
Gustafsson, Jan-Ake ;
Regitz-Zagrosek, Vera .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2010, 298 (06) :R1597-R1606
[7]   Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes [J].
Gerstein, Hertzel C. ;
Sattar, Naveed ;
Rosenstock, Julio ;
Ramasundarahettige, Chinthanie ;
Pratley, Richard ;
Lopes, Renato D. ;
Lam, Carolyn S. P. ;
Khurmi, Nardev S. ;
Heenan, Laura ;
Del Prato, Stefano ;
Dyal, Leanne ;
Branch, Kelley .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (10) :896-907
[8]   The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial [J].
Gerstein, Hertzel C. ;
Hart, Robert ;
Colhoun, Helen M. ;
Diaz, Rafael ;
Lakshmanan, Mark ;
Botros, Fady T. ;
Probstfield, Jeffrey ;
Riddle, Matthew C. ;
Ryden, Lars ;
Atisso, Charles Messan ;
Dyal, Leanne ;
Hall, Stephanie ;
Avezum, Alvaro ;
Basile, Jan ;
Conget, Ignacio ;
Cushman, William C. ;
Hancu, Nicolae ;
Hanefeld, Markolf ;
Jansky, Petr ;
Keltai, Matyas ;
Lanas, Fernando ;
Leiter, Lawrence A. ;
Lopez-Jaramillo, Patricio ;
Cardona Munoz, Ernesto German ;
Pogosova, Nana ;
Raubenheimer, Peter J. ;
Shaw, Jonathan E. ;
Sheu, Wayne H-H ;
Temelkova-Kurktschiev, Theodora .
LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (02) :106-114
[9]   Heart Disease and Stroke Statistics-2013 Update A Report From the American Heart Association [J].
Go, Alan S. ;
Mozaffarian, Dariush ;
Roger, Veronique L. ;
Benjamin, Emelia J. ;
Berry, Jarett D. ;
Borden, William B. ;
Bravata, Dawn M. ;
Dai, Shifan ;
Ford, Earl S. ;
Fox, Caroline S. ;
Franco, Sheila ;
Fullerton, Heather J. ;
Gillespie, Cathleen ;
Hailpern, Susan M. ;
Heit, John A. ;
Howard, Virginia J. ;
Huffman, Mark D. ;
Kissela, Brett M. ;
Kittner, Steven J. ;
Lackland, Daniel T. ;
Lichtman, Judith H. ;
Lisabeth, Lynda D. ;
Magid, David ;
Marcus, Gregory M. ;
Marelli, Ariane ;
Matchar, David B. ;
McGuire, Darren K. ;
Mohler, Emile R. ;
Moy, Claudia S. ;
Mussolino, Michael E. ;
Nichol, Graham ;
Paynter, Nina P. ;
Schreiner, Pamela J. ;
Sorlie, Paul D. ;
Stein, Joel ;
Turan, Tanya N. ;
Virani, Salim S. ;
Wong, Nathan D. ;
Woo, Daniel ;
Turner, Melanie B. .
CIRCULATION, 2013, 127 (01) :E6-E245
[10]   Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial [J].
Heerspink, Hiddo J. L. ;
Sattar, Naveed ;
Pavo, Imre ;
Haupt, Axel ;
Duffin, Kevin L. ;
Yang, Zhengyu ;
Wiese, Russell J. ;
Tuttle, Katherine R. ;
Cherney, David Z. I. .
LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (11) :774-785